<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-339 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-339</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-339</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-216155587</p>
                <p><strong>Paper Title:</strong> <a href="https://e-journal.unair.ac.id/JR/article/download/17304/9704" target="_blank">Triple Mutation Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719s), 20 (T790m), and 21 (L858r) in A Male Patient with Lung Adenocarcinoma: A Case Report</a></p>
                <p><strong>Paper Abstract:</strong> Background: Lung cancer is one of the deadliest cancers in the world. The percentage of non-small cell lung cancer (NSCLC) is about 80% of the incidence of lung cancer. A type of NSCLC, adenocarcinoma, is usually found in the presence of epidermal growth factor receptor (EGFR) mutations. Case: A male patient aged 70 years old, an active smoker, works as a farmer. He experienced shortness of breath and chest pain for three months. There was no family history of suffering from malignancy. The cytology result of the right pleural fluid indicated adenocarcinoma. He was diagnosed with pulmonary adenocarcinoma (D) stage IV positive mutation of EGFR exon 18 (G719S), 20 (T790M), and 21 (L858R) with Karnofsky score of 70. He could survive for more than 11 months with the treatment of EGFR TKI, and received a good therapeutic response. Initially, for the first six months, it was such a progressive disease, and for the next eleven months it became stable. Discussion: Lung adenocarcinoma has a higher EGFR mutation rate than that of other types of NSCLC. EGFR mutations usually occur in the first four exons that have a code for Tyrosine Kinase (TK), such as deletion (usually five amino acids) in exon 19 and leucine-to-arginine missens mutations in codon 858 of exon 21 (L858R). Conclusion: In addition to exon mutations found in this case, cells in the tumor will continue to grow and develop into new mutants that are immune to drugs and rapidly split themselves into new, different forms. The therapy for complex mutations is still being developed. EGFR TKI therapy in this patient had a relatively good response. Further understanding of molecular biology of lung cancer is seriously required.</p>
                <p><strong>Cost:</strong> 0.017</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e339.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e339.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Global EGFR prevalence (MutMapi)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR mutation prevalence by region/ethnicity (systematic review / MutMapi)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Summary prevalence statements from the paper: EGFR mutations in lung adenocarcinoma are substantially more frequent in East Asian populations than in non-Asian populations (United States, Western Europe), with commonly different exon distributions (exon 19 deletions and exon 21 L858R most frequent).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (Mutmapii).</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>East Asian; United States (non-Asian); Western European (non-Asian)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Global / multiple regions (systematic review referenced in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>United States: ~10% (adenocarcinoma); East Asia: ~35% (adenocarcinoma); Western Europe: ~10-15% (NSCLC overall) as reported in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Most common: exon 19 deletions and exon 21 L858R; other exons (18, 20) are rarer.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td>East Asia ~35% vs United States ~10% (adenocarcinoma); Western Europe reported ~10-15% of NSCLC.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>The paper cites prior work that EGFR mutations are commonly associated with never-smokers (Pao et al.), but also reports an Asia-Pacific figure in the text that appears to show a high proportion in smokers (see separate Asia-Pacific entry). The paper therefore contains both statements from different sources.</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Paper reports in Asia-Pacific region ~60% of EGFR mutations occurred in women and ~37% in men (as cited).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>The paper discusses genetic explanations generally (germline versus somatic mutations) and explicitly notes reports of germline T790M and racial observations (e.g., T790M reported in white patients in one cited study), implying genetic predisposition may contribute to ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td>Authors list environmental carcinogens (benzo[a]pyrene in cigarette smoke, nitrosamines in preserved/canned/salted foods, ultraviolet light DNA damage) as external factors that can cause genetic damage and potentially contribute to geographic/ethnic differences in mutation patterns.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>Paper cites lifestyle contributors such as smoking and dietary exposures (preserved/canned/salted fish) as possible contributors to carcinogenesis and therefore to differing mutation frequencies across populations.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>Paper highlights incomplete data and heterogeneous reporting (detection methods, sample types) which can affect apparent geographic/ethnic distribution; also notes potential germline variants (detection of de novo/germline T790M) and intratumoral heterogeneity as complicating factors.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Paper reports EGFR exon 19 deletions and exon 21 L858R are the mutations most sensitive to first-generation EGFR TKIs, and cites a meta-analysis showing exon 19 deletions are associated with longer PFS than L858R; no ethnicity-specific drug-response rates are provided in the paper.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e339.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e339.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Japan complex-mutation findings</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Japanese series reporting distribution of single vs. complex EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Cited Japanese data in the paper report high proportion of single EGFR mutations (~91%), dual mutations ~9%, and complex mutations reported at ~6.6%; exon 18 double/triple forms found in ~4% of EGFR-mutated cases in a Japanese study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Japanese (East Asian)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Japan</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Within EGFR-mutated tumors: single mutations ~91%, dual mutations ~9%, complex mutations reported ~6.6%; exon 18 double/triple forms ~4% of EGFR-mutated cases (as reported in the paper).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Includes exon 18 (G719S), exon 19 deletions, exon 20 (T790M), exon 21 (L858R); exon 18 forms rare.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (NSCLC) (EGFR-mutated subset)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>The paper cites that in some Japanese data the efficacy of gefitinib in patients with complex EGFR mutations was similar to those with a single mutation (examples: CR, PR, SD, PD distributed among 12 patients with complex mutations), but no ethnicity-specific response rates beyond the Japanese series are given.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e339.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e339.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>French ERMETIC-IFCT study</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Rare EGFR Exon 18 and Exon 20 Mutations in Non-Small-Cell Lung Cancer on 10 117 Patients: A Multicentre Observational Study by the French ERMETIC-IFCT Network</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Large French multicentre observational series (cited in the paper) reporting frequencies of rare exon 18 and 20 mutations and providing distributions among EGFR mutation types (e.g., proportions of exon 19 in-frame deletions and exon 21 L858R among mutated cases).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Rare EGFR Exon 18 and Exon 20 Mutations in Non-Small-Cell Lung Cancer on 10 117 Patients: A Multicentre Observational Study by the French ERMETIC-IFCT Network</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Predominantly European / French (white)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>France (multicentre)</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>10,117</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Paper cites that among EGFR-mutated cases, exon 19 in-frame deletions accounted for ~85-90% (of deletion events) and exon 21 L858R substitutions ~40-45%; exon 20 (T790M) incidence reported as low (~1% in one French dataset cited).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 in-frame deletions (majority of deletions), exon 21 L858R; exon 18 and exon 20 mutations are rare (exon 20 T790M reported ~1% in one cited French dataset).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Non-small-cell lung cancer, adenocarcinoma subset</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>The paper cites that exon 20 T790M is associated with resistance to first-generation EGFR TKIs; French data reported low T790M incidence but specific population response rates are not provided in this case report.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e339.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e339.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Li S et al. Chinese cohort</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Coexistence of EGFR with KRAS, or BRAF, or PIK3CA Somatic Mutations in Lung Cancer: A Comprehensive Mutation Profiling from 5125 Chinese Cohorts (data subset referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Cited Chinese data (Li S et al.) reported exon-specific frequencies among 2,368 EGFR-mutated patients: exon 19 ~48.11%, exon 21 ~45.40%, exon 20 ~3.92%, and single exon 18 mutations ~2.57% (values reported in the paper).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Coexistence of EGFR with KRAS, or BRAF, or PIK3CA Somatic Mutations in Lung Cancer: A Comprehensive Mutation Profiling from 5125 Chinese Cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Chinese (East Asian)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>China</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>2,368 (EGFR-mutated patients cited in text)</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Within the EGFR-mutated subset cited: exon 19 ~48.11%, exon 21 ~45.40%, exon 20 ~3.92%, exon 18 (single mutations) ~2.57% (as reported in the paper).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 deletions, exon 21 L858R, exon 20 mutations (including T790M), exon 18 G719S (rare).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (EGFR-mutated subset)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>Not directly reported for the cohort in the case report text; paper generally discusses variable sensitivity by exon (exon 19 and 21 being more sensitive).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e339.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e339.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>T790M racial/germline observation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Observation that EGFR T790M has been reported in white patients and may represent germline (de novo) mutation in some reports</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The case report cites a study (referred to as 'Yannyan et al.' in the text) which described exon T790M occurring in white patients and being considered as germline in some cases; T790M is otherwise relatively rare and often appears as part of complex mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Reported in white patients (cited study)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>T790M reported as uncommon overall (~1% in one French dataset cited; ~5% of EGFR mutations in other statements), with some reports of occurrence in white patients and as germline/de novo in those reports.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>EGFR exon 20 T790M (noted as sometimes germline/de novo and often part of complex mutations).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td>Text explicitly notes the possibility of germline (hereditary) T790M explaining occurrence in some individuals and mentions racial observation (reported in white patients) as supportive of genetic contribution.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma / NSCLC</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td>T790M is associated with resistance to first-generation EGFR TKIs; paper notes T790M frequently underlies acquired resistance and is targeted by third-generation drugs (osimertinib).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e339.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e339.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing Asian and non-Asian populations, and any proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Asia-Pacific demographic observations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Asia-Pacific region EGFR mutation demographic figures (as cited in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper reports region-level figures for the Asia-Pacific: that ~60% of EGFR mutations occur in women (37% in men) and an Asia-Pacific figure stating 64% of EGFR mutations occurred in smokers and 33% in non-smokers (both figures are presented in the paper's discussion).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_ethnicity</strong></td>
                            <td>Asia-Pacific (mixed East/South-East Asian populations)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population_location</strong></td>
                            <td>Asia-Pacific region</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_other_ethnicities</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>comparative_frequency_data</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_correlation</strong></td>
                            <td>Paper contains two different cited impressions: classic literature linking EGFR mutations to never-smokers (Pao et al.) and an Asia-Pacific figure in the text reporting a high proportion in smokers (64% in smokers vs 33% in non-smokers) â€” the paper does not resolve these discrepant citations.</td>
                        </tr>
                        <tr>
                            <td><strong>gender_correlation</strong></td>
                            <td>Paper reports that in the Asia-Pacific region ~60% of EGFR mutations occurred in women and ~37% in men (cited).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_genetic</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_environmental</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_lifestyle</strong></td>
                            <td>Paper implies lifestyle factors (smoking, diet) could relate to cancer and mutation occurrence and lists these as possible contributors in general discussion, but no Asia-specific causal mechanism is formally proposed.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation_other</strong></td>
                            <td>The paper notes incomplete data and reporting heterogeneity in the region that may affect observed distributions.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Adenocarcinoma (NSCLC)</td>
                        </tr>
                        <tr>
                            <td><strong>response_to_egfr_inhibitors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (Mutmapii). <em>(Rating: 2)</em></li>
                <li>Rare EGFR Exon 18 and Exon 20 Mutations in Non-Small-Cell Lung Cancer on 10 117 Patients: A Multicentre Observational Study by the French ERMETIC-IFCT Network <em>(Rating: 2)</em></li>
                <li>Coexistence of EGFR with KRAS, or BRAF, or PIK3CA Somatic Mutations in Lung Cancer: A Comprehensive Mutation Profiling from 5125 Chinese Cohorts. <em>(Rating: 2)</em></li>
                <li>Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors. <em>(Rating: 2)</em></li>
                <li>Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. <em>(Rating: 1)</em></li>
                <li>Patients with Exon 19 Deletion were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation After First-Line EGFR-TKIS for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>